A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of huntington’s disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Huntington’s disease (HD) is a neurodegenerative disorder, ofwhich pathogenesis is caused by a polyglutamine expansion inthe amino-terminus of huntingtin gene that resulted in the aggregationof mutant HTT proteins. HD is characterized by progressivemotor dysfunction, cognitive impairment and neuropsychiatricdisturbances. Histone deacetylase 6 (HDAC6), amicrotubule-associated deacetylase, has been shown to inducetransport- and release-defect phenotypes in HD models, whilsttreatment with HDAC6 inhibitors ameliorates the phenotypiceffects of HD by increasing the levels of α-tubulin acetylation,as well as decreasing the accumulation of mutant huntingtin(mHTT) aggregates, suggesting HDAC6 inhibitor as a HD therapeutics. In this study, we employed in vitro neural stem cell(NSC) model and in vivo YAC128 transgenic (TG) mouse modelof HD to test the effect of a novel HDAC6 selective inhibitor,CKD-504, developed by Chong Kun Dang (CKD PharmaceuticalCorp., Korea). We found that treatment of CKD-504 increasedtubulin acetylation, microtubule stabilization, axonaltransport, and the decrease of mutant huntingtin protein invitro. From in vivo study, we observed CKD-504 improved thepathology of Huntington’s disease: alleviated behavioral deficits,increased axonal transport and number of neurons, restoredsynaptic function in corticostriatal (CS) circuit, reduced mHTTaccumulation, inflammation and tau hyperphosphorylation inYAC128 TG mouse model. These novel results highlight CKD-504as a potential therapeutic strategy in HD.
Abstract
Huntington’s disease (HD) is a neurodegenerative disorder, ofwhich pathogenesis is caused by a polyglutamine expansion inthe amino-terminus of huntingtin gene that resulted in the aggregationof mutant HTT proteins. HD is characterized by progressivemotor dysfunction, cognitive impairment and neuropsychiatricdisturbances. Histone deacetylase 6 (HDAC6), amicrotubule-associated deacetylase, has been shown to inducetransport- and release-defect phenotypes in HD models, whilsttreatment with HDAC6 inhibitors ameliorates the phenotypiceffects of HD by increasing the levels of α-tubulin acetylation,as well as decreasing the accumulation of mutant huntingtin(mHTT) aggregates, suggesting HDAC6 inhibitor as a HD therapeutics. In this study, we employed in vitro neural stem cell(NSC) model and in vivo YAC128 transgenic (TG) mouse modelof HD to test the effect of a novel HDAC6 selective inhibitor,CKD-504, developed by Chong Kun Dang (CKD PharmaceuticalCorp., Korea). We found that treatment of CKD-504 increasedtubulin acetylation, microtubule stabilization, axonaltransport, and the decrease of mutant huntingtin protein invitro. From in vivo study, we observed CKD-504 improved thepathology of Huntington’s disease: alleviated behavioral deficits,increased axonal transport and number of neurons, restoredsynaptic function in corticostriatal (CS) circuit, reduced mHTTaccumulation, inflammation and tau hyperphosphorylation inYAC128 TG mouse model. These novel results highlight CKD-504as a potential therapeutic strategy in HD.
참고문헌 (28)
- Pan L, "Huntington’s disease : new frontiers in therapeutics", Curr Neurol Neurosci Rep, 21, pp.10~ (2021)
- Ghosh R, "Clinical features of Huntington’s disease", Adv Exp Med Biol, 1049, pp.1~28 (2018)
- Arrowsmith CH, "Epigenetic protein families : a new frontier for drug discovery", Nat Rev Drug Discov, 11, pp.384~400 (2012)
- Kazantsev AG, "Therapeutic application of histone deacetylase inhibitors for central nervous system disorders", Nat Rev Drug Discov, 7, pp.854~868 (2008)
- Bishton MJ, "Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia", Blood, 117, pp.3658~3668 (2011)
- Subramanian S, "Clinical toxicities of histone deacetylase inhibitors", Pharmaceuticals(Basel), 3, pp.2751~2767 (2010)
- Noack M, "HDAC6inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes", Glia, 62, pp.535~547 (2014)
- Zhang Y, "HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo", EMBO J, 22, pp.1168~1179 (2003)
- Reed NA, "Microtubule acetylation promotes kinesin-1 binding and transport", Curr Biol, 16, pp.2166~2172 (2006)
- Trushina E, "Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro", Mol Cell Biol, 24, pp.8195~8209 (2004)
- Dompierre JP, "Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation", J Neurosci, 27, pp.3571~3583 (2007)
- Zhang Y, "Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally", Mol Cell Biol, 28, pp.1688~1701 (2008)
- Hinckelmann MV, "Releasing the brake : restoring fast axonal transport in neurodegenerative disorders", Trends Cell Biol, 23, pp.634~643 (2013)
- Govindarajan N, "Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease", EMBO Mol Med, 5, pp.52~63 (2013)
- Selenica ML, "Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition", Alzheimers Res Ther, 6, pp.12~ (2014)
- d’Ydewalle C, "HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease", Nat Med, 17, pp.968~974 (2011)
- Yang SS, "The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease", Transl Neurodegener, 6, pp.19~ (2017)
- Reddy RG, "Crafting carbazole-based vorinostat and tubastatin-a-like histone deacetylase(HDAC)inhibitors with potent in vitro and in vivo neuroactive functions", ACS Omega, 4, pp.17279~17294 (2019)
- Choi H, "Acetylation changes tau interactome to degrade tau in Alzheimer’s disease animal and organoid models", Aging Cell, 19, pp.e13081~ (2020)
- Ha N, "A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A", Br J Pharmacol, 177, pp.5096~5113 (2020)
- Crook ZR, "Huntington’s disease : can mice lead the way to treatment?", Neuron, 69, pp.423~435 (2011)
- Sapp E, "Native mutant huntingtin in human brain : evidence for prevalence of full-length monomer", J Biol Chem, 287, pp.13487~13499 (2012)
- Slow EJ, "Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease", Hum Mol Genet, 12, pp.1555~1567 (2003)
- Joshi PR, "Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease", J Neurosci, 29, pp.2414~2427 (2009)
- Butler KV, "Rational design and simple chemistry yield a superior, neuroprotective HDAC6inhibitor, tubastatin A", J Am Chem Soc, 132, pp.10842~10846 (2010)
- Choi D, "Fluorescent retrograde neuronal tracers that label the rat facial nucleus : a comparison of Fast Blue, Fluoro-ruby, Fluoroemerald, Fluoro-Gold and DiI", J Neurosci Methods, 117, pp.167~172 (2002)
- Fernandez-Nogales M, "Huntington’s disease is a four-repeat tauopathy with tau nuclear rods", Nat Med, 20, pp.881~885 (2014)
- Avila J, "Role of tau protein in both physiological and pathological conditions", Physiol Rev, 84, pp.361~384 (2004)